Sanofi has signed a partnership deal worth potentially US $845 million with Voyager
Therapeutics, a comparatively small biotech firm, becoming the latest in a series of major pharmaceutical firms to commit financially to gene therapy research.

According to a joint statement by the two companies, Genzyme, the Sanofi subsidiary involved in the deal, will work collaboratively with
Voyager Therapeutics to develop and ultimately commercialise 'novel
adeno-associated virus (AAV) gene therapies for Parkinson's disease, Friedreich’s ataxia, Huntington’s disease and other debilitating central
nervous system disorders.

Dr Steven
Paul, president
and CEO of Voyager Therapeutics, says the alliance will ensure both companies
'are at the forefront of converting the promise of gene therapy into innovative
therapies for CNS disorders that make a meaningful difference in patients'
lives'.

According
to the agreement, Voyager Therapeutics will oversee research and development of
the specified gene therapy programmes, receiving an initial US $100 million upfront
payment from Genzyme, including US $65 million in cash.

Should
the programmes be successful and ultimately produce commercialised therapies,
Voyager Therapeutics could receive up to US $745 million in 'development and sales
milestones payments' and royalties.

Currently
Voyager has two products - in Parkinson's disease and Friedreich's ataxia - in early
clinical development, and others in preclinical trials.

Voyager
Therapeutics will retain the rights to the Parkinson's and Friedreich’s ataxia programmes
in the USA, and Genzyme will hold outside-US rights. The two companies plan to share
any eventual US profits from the project in Huntington's disease. Genzyme will have licensing options for
several other programmes after completion of proof-of-concept clinical trials.

Voyager's AAV gene
therapies involve silencing disease-causing gene mutations or replacing them with
healthy versions. The AAV viruses are used as vectors, delivering the repair genes to
the target.

According to industry
analysts FierceBiotech, the company is 'also
at work on new viral delivery vehicles that could mark a major improvement in
the field'.

In
the last year, three other important pharmaceutical players have
made similar collaborative deals with biotech firms to develop gene therapies.

Genzyme's
interest in gene therapy goes back over twenty years, enduring a fallow period
when the technique appeared to many too problematic to ever bear commercial
fruit. But last year Glybera, produced by the Dutch biotech UniQure, became the
first gene therapy product to go on sale in Europe (see BioNews 782).

'We really carried the torch for years when some other companies left
the space,' Mark Barrett, Genzyme's vice president of business development, told
FierceBiotech.